SAVOR ( Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus ) randomised 16,492 patients with Type 2 Diabetes Mellitus and a high-risk of cardiovascular events treated with current per oral antidiabetics and patients treated with saxagliptin or placebo .